FR05C0033I1 - - Google Patents

Info

Publication number
FR05C0033I1
FR05C0033I1 FR05C0033C FR05C0033I1 FR 05C0033 I1 FR05C0033 I1 FR 05C0033I1 FR 05C0033 C FR05C0033 C FR 05C0033C FR 05C0033 I1 FR05C0033 I1 FR 05C0033I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR05C0033I1 publication Critical patent/FR05C0033I1/fr
Application granted granted Critical
Publication of FR05C0033I2 publication Critical patent/FR05C0033I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
FR05C0033C 1993-10-18 2005-08-09 R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate Active FR05C0033I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13951793A 1993-10-18 1993-10-18
PCT/US1994/011567 WO1995011016A1 (fr) 1993-10-18 1994-10-12 R-enantiomere de n-propargyl-1-amino-indane, sels, compositions et utilisation de ce compose

Publications (2)

Publication Number Publication Date
FR05C0033I1 true FR05C0033I1 (fr) 2005-09-30
FR05C0033I2 FR05C0033I2 (fr) 2006-12-29

Family

ID=22487049

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0033C Active FR05C0033I2 (fr) 1993-10-18 2005-08-09 R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate

Country Status (17)

Country Link
EP (1) EP0812190B1 (fr)
JP (3) JPH09505806A (fr)
AT (1) ATE284208T1 (fr)
AU (1) AU1253495A (fr)
CA (1) CA2174449C (fr)
DE (2) DE69434178T2 (fr)
DK (1) DK0812190T3 (fr)
ES (1) ES2235170T3 (fr)
FR (1) FR05C0033I2 (fr)
HU (1) HU226138B1 (fr)
IL (1) IL111240A (fr)
LU (1) LU91191I2 (fr)
MX (1) MXPA94008019A (fr)
NL (1) NL300205I2 (fr)
PT (1) PT812190E (fr)
WO (1) WO1995011016A1 (fr)
ZA (1) ZA948013B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
HU225986B1 (en) * 1994-01-10 2008-02-28 Teva Pharma Use of 1-aminoindan derivatives for preparing pharmaceutical compns. and 1-aminoindan derivatives
WO1996024346A1 (fr) * 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Composes deprenyle pour le traitement du glaucome
CA2214026C (fr) * 1995-03-02 2007-10-16 R.P. Scherer Limited Compositions pharmaceutiques comprenant des inhibiteurs de la monoamine oxydase b
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
CA2319318A1 (fr) * 1998-01-27 1999-07-29 Thomas N. Thomas Methodes de traitement utilisant des inhibiteurs mao-a et mao-b tel que le l-deprenyle
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
CA2387394C (fr) 1999-10-27 2009-08-18 Teva Pharmaceutical Industries, Ltd. Utilisation de derives de 1-aminoindan pour le traitement de la manie liee a la psychose maniacodepressive
WO2004045515A2 (fr) * 2002-11-15 2004-06-03 Teva Pharmaceutical Industries, Ltd. Utilisation de rasagiline, avec ou sans riluzole, pour traiter la sclerose laterale amyotrophique
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (fr) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
KR20130129300A (ko) * 2005-02-23 2013-11-27 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
WO2007061717A2 (fr) * 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Procedes de separation d’amino-indanes propargyles
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1956904B1 (fr) 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Ladostigil a faible dose pour le traitement du déficit cognitif léger
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
AU2007235517B2 (en) * 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (fr) 2006-08-18 2008-02-27 Ratiopharm GmbH De nouveaux sels de la substance active rasagiline
ES2420124T3 (es) 2006-12-14 2013-08-22 Teva Pharmaceutical Industries Ltd. Sal de tanato de rasagilina
ZA200903903B (en) 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
CA2698695A1 (fr) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Procede pour traiter le glaucome avec la rasagiline
KR101523195B1 (ko) 2007-12-24 2015-05-27 시플라 리미티드 프로파길화된 아미노인단 유도체의 합성방법
US20110117200A1 (en) * 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
US7781616B2 (en) 2008-05-23 2010-08-24 Medichem, S.A. Method for obtaining an aminoindan mesylate derivative
EP2280929B1 (fr) * 2008-06-02 2018-01-31 Generics [UK] Limited Methode amelioree de preparation de rasagiline
AU2009254927B2 (en) * 2008-06-02 2014-03-13 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
EP2328861A2 (fr) 2008-07-11 2011-06-08 Synthon BV Polymorphes de chlorhydrate de rasagiline
WO2010007181A2 (fr) * 2008-07-18 2010-01-21 Medichem, S.A. Nouvelles formes de sels d’un dérivé d’aminoindane
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
AU2010270254A1 (en) 2009-07-09 2012-02-02 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (fr) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Nouveaux sels de rasagiline
CA2785501A1 (fr) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-ceto-n-propargyl-1-aminoindane
EP2519496A2 (fr) * 2009-12-30 2012-11-07 Actavis Group Ptc Ehf Formes à l'état solide de sels de rasagiline
LT2531181T (lt) * 2010-02-03 2019-07-10 Pharma Two B Ltd. Rasagilino uždelsto atpalaidavimo kompozicijos ir jų panaudojimas
WO2011121607A2 (fr) 2010-03-29 2011-10-06 Cadila Healthcare Limited Composé de rasagiline et sels pharmaceutiquement acceptables de celui-ci
EP2389927A1 (fr) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations pharmaceutiques de rasagiline
CN102464589A (zh) * 2010-11-17 2012-05-23 凯瑞斯德生化(苏州)有限公司 雷沙吉兰、其甲磺酸盐及其中间体的制备方法
US8901352B2 (en) 2011-01-13 2014-12-02 Nobel Ilaç Sanayii Ve Ticaret A.S. Method for the synthesis of rasagiline
EP2681186B1 (fr) 2011-03-03 2016-05-11 Synthon BV Procédé de résolution de 1-aminoindane
EP2705021A2 (fr) 2011-05-04 2014-03-12 Cadila Healthcare Limited Rasagiline et ses sels pharmaceutiquement acceptables
EA201490761A1 (ru) * 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
MX343986B (es) 2012-03-21 2016-12-01 Synthon Bv Composiciones farmaceuticas estabilizadas que comprenden sales de rasagilina.
WO2013175493A1 (fr) 2012-04-09 2013-11-28 Cadila Healthcare Limited Compositions pharmaceutiques orales stables
ES2502140T1 (es) 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
ES2524865T1 (es) 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
IN2013MU01782A (fr) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation

Also Published As

Publication number Publication date
WO1995011016A1 (fr) 1995-04-27
PT812190E (pt) 2005-04-29
ES2235170T3 (es) 2005-07-01
DE122005000044I2 (de) 2007-09-13
JPH09505806A (ja) 1997-06-10
HU9601012D0 (en) 1996-06-28
CA2174449A1 (fr) 1995-04-27
AU1253495A (en) 1995-05-08
EP0812190A4 (fr) 1998-03-04
MXPA94008019A (es) 2004-08-10
DE122005000044I1 (de) 2005-12-22
EP0812190A1 (fr) 1997-12-17
IL111240A0 (en) 1994-12-29
DE69434178T2 (de) 2005-12-01
ATE284208T1 (de) 2004-12-15
DE69434178D1 (de) 2005-01-13
NL300205I2 (nl) 2006-03-01
DK0812190T3 (da) 2005-04-11
HUT77934A (hu) 1998-11-30
CA2174449C (fr) 2007-01-16
ZA948013B (en) 1995-05-31
JP2010018626A (ja) 2010-01-28
NL300205I1 (nl) 2005-10-03
JP2003160481A (ja) 2003-06-03
FR05C0033I2 (fr) 2006-12-29
LU91191I2 (fr) 2005-10-10
IL111240A (en) 2001-10-31
EP0812190B1 (fr) 2004-12-08
HU226138B1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
FR09C0038I2 (fr)
FR2707010B1 (fr)
FR05C0033I1 (fr)
FR06C0004I1 (fr)
TW248619B (fr)
FR2707020B1 (fr)
FR2706968B1 (fr)
FR2710080B1 (fr)
EP0643239A3 (fr)
FR2711603B1 (fr)
FR2706894B1 (fr)
GB9406293D0 (fr)
FR2707045B1 (fr)
FR2710424B1 (fr)
IN176945B (fr)
IN174871B (fr)
DK14293D0 (fr)
ECSDI930124S (fr)
DK22193A (fr)
IN177399B (fr)
IN177163B (fr)
IN177143B (fr)
IN177090B (fr)
IN176973B (fr)
DK109393D0 (fr)